Jubilant Ingrevia H1 Profit After Tax surged by 34%

 

  • Jubilant Ingrevia H1 Profit After Tax surged by 34%



  • Markets Update: Across the broader Chemicals Industry, witnessing a steady recovery in volumes, even as pricing remains under pressure across all segments. 
  • At the same time, many global players, especially players in Europe are reporting deteriorating financials due to weaker demand, continued pricing pressure and elevated energy costs. 
  • The pharmaceutical end-use market continues to show steady volume growth, supported by stable pricing. 
  • Saw consistent volume expansion across CDMO and Fine-Chemicals products. 
  • Additionally, saw a marginal recovery in volumes last quarter within the Paracetamol segment. 
  • The global Agrochemical sector has successfully moved beyond the inventory destocking phase, with volumes now stabilizing and showing clear signs of growth. 
  • This upward momentum is supported by strong volume expansion on both YoY and QoQbasis. 
  • Pricing in the segment has remained stable over the past few quarters, reinforcing the recovery trend. 
  • The Nutrition market recorded steady volume growth during the quarter though feed-grade vitamins pricing showed short-term volatility globally and in India. 
  • Niacinamide demand showed a modest uptick as customer purchasing activity resumed, following subdued volumes at the start of the financial year. Choline volumes traditionally dip in Q2 (versus Q1) due to festivals, however have seen a notable YoY volume increase. 
  • Business Update: The Specialty Chemicals segment continued on its revenue growth trajectory and reported 25%+ margins during the quarter, driven primarily by strong performance in Fine Chemicals and CDMO sales. 
  • Successfully delivered volumes against one of new Agro CDMO innovator contract in Q2. 
  • In last few quarters, have added 10+ new molecules in CDMO/Fine chemicals portfolio, which have already started to show in FY26 revenues, and are expected to contribute 1200cr+ of peak annual revenues in coming years. 
  • Have another 10+ opportunities in advanced stages of discussions, which  hope to convert in coming quarters. 
  • The Nutrition and Health Solutions business segment grew volumes on YoY basis, with volume growth seen across most segments. 
  • Revenue remained steady as overall pricing in the nutrition segment was slightly lower due to competitive pressures, which had a bearing on margins as well. 
  • New cGMP facility is ramping up and continues to drive growth in cosmetic-grade sales. 
  • The EU’s anti-dumping duty on Chinese origin Choline products are creating a good pipeline which would get realized in coming quarters, with early orders already booked in Q2. 
  • In the Chemical Intermediates segment,  strategic initiatives on Ethyl Acetate and Acetic Anhydride sales drove a notable QoQ and YoY growth in volumes and revenue, clocking highest quarterly revenue and volumes in last six quarters. 
  • Have continued to secure and grow our domestic and global market share despite market pricing pressures. 
  • With sustained focus on cost efficiency, successfully maintained margins in line with the previous quarter. 
  • Future Outlook: Looking ahead to H2’FY26, expect continued growth momentum, fueled by progress in Specialty Chemicals and Nutrition businesses, along with an expected part-recovery in the Acetyls portfolio. 
  • Also on track to start serving major CDMO order in early 2026, a milestone that is expected to significantly accelerate growth trajectory in the CDMO segment. 
  • To meet the increased demand in CDMO,  did ground-breaking of new MPP in Gajraula, which  hope to complete by late 2026.

Comments

Post a Comment

Popular posts from this blog

Transcript of NMDC Limited post Q4 & FY 2024-25 Results

Image
Transcript of NMDC Limited post Q4 & FY 2024-25 Results Growth in PAT on an annual or a year-on-year 12-month basis of around 19% and PBT after exceptional item of around 16% Gold operations in Legacy, the first year was have also stabilized Legacy in the last 2 months, 3 months.  And hopefully, in this financial year, Legacy would also be showing good profits IMPORTS India which imports around 55 million, 60 million tons is likely to go up to 150 million to 160 million tons of import for India in terms of coking coal.  Have entered into arrangement with SAIL 60% of total sales as of date is routed through SAIL because send it to their stocking yard.  So based on the user charge, they also market mmdc products 40% still Nmdc market directly in terms of HR coils 2025 year will be much more substantially action packed in terms of NMDC Open new mines within India, coal and iron ore Outside India, we hope to acquire a few mines.  This will be a year where it will be ...
Read more

Looking to park some excess funds for the short term.?

Image
Looking to park some excess funds for the short term.  LiquidBeES by Nippon - has been the default choice for years. But lately, it’s become muscle memory to run everything past ChatGPT.  Just a quick: “Is there a better option than LiquidBeES?” It turns out, there is.  LIQUIDCASE by Zerodha AMC.  Difference was not subtle and decision was easier : - Expense ratio: Less than half of LiquidBeES - Net returns: ~6.2% vs ~5.7% (1-year annualized) - Same safety, same liquidity - AUM already >1/3rd of LiquidBeES in record time This is how discovery is changing. And this is how smart products go viral. Zerodha didn’t try to educate the market.  Discovery is no longer driven by ads or advisors.  It’s driven by habit, trust, and tools like ChatGPT. And when you get it right, traction follows fast. I won’t be surprised if LIQUIDCASE overtakes LiquidBeES in under 18 months. Thank you for contacting Rounaq! Please let us know how we can help you.  About me :...
Read more

𝐖𝐡𝐲 𝐃𝐨 𝐍𝐑𝐈𝐬 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚?

Image
  𝐖𝐡𝐲 𝐃𝐨 𝐍𝐑𝐈𝐬 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚? Whether you're living in the US, UAE, UK, or Singapore; India continues to be a hotspot for wealth creation. But why do so many NRIs still invest here? Here’s why 👇 ✅ Higher Returns – Indian equity markets, mutual funds, and even fixed deposits offer attractive long-term returns. ✅ Tax-Free Income – Interest from NRE and FCNR deposits is tax-free in India. Plus, DTAA helps avoid double taxation. ✅ Currency Edge – You invest in INR, and with the right timing, your gains in foreign currency terms could be even higher. ✅ Diversification – Indian assets like gold, real estate, and stocks add balance to a global portfolio. ✅ Future Ready – Planning to return to India someday? Build your base early with property or retirement-focused investments. ✅ Emotional Roots – Beyond numbers, India is still home. 💡 Whether it’s for wealth creation, retirement planning, or building assets back home, India offers a solid mix of growth + stability...
Read more